• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

支持疫苗产品开发的患者安全知识图谱。

A patient safety knowledge graph supporting vaccine product development.

机构信息

Biomedical Informatics and Medical Education, University of Washington, Seattle, Washington, USA.

AstraZeneca PLC, Gaithersburg, Maryland, USA.

出版信息

BMC Med Inform Decis Mak. 2024 Jan 4;24(1):10. doi: 10.1186/s12911-023-02409-8.

DOI:10.1186/s12911-023-02409-8
PMID:38178113
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10768450/
Abstract

BACKGROUND

Knowledge graphs are well-suited for modeling complex, unstructured, and multi-source data and facilitating their analysis. During the COVID-19 pandemic, adverse event data were integrated into a knowledge graph to support vaccine safety surveillance and nimbly respond to urgent health authority questions. Here, we provide details of this post-marketing safety system using public data sources. In addition to challenges with varied data representations, adverse event reporting on the COVID-19 vaccines generated an unprecedented volume of data; an order of magnitude larger than adverse events for all previous vaccines. The Patient Safety Knowledge Graph (PSKG) is a robust data store to accommodate the volume of adverse event data and harmonize primary surveillance data sources.

METHODS

We designed a semantic model to represent key safety concepts. We built an extract-transform-load (ETL) data pipeline to parse and import primary public data sources; align key elements such as vaccine names; integrated the Medical Dictionary for Regulatory Activities (MedDRA); and applied quality metrics. PSKG is deployed in a Neo4J graph database, and made available via a web interface and Application Programming Interfaces (APIs).

RESULTS

We import and align adverse event data and vaccine exposure data from 250 countries on a weekly basis, producing a graph with 4,340,980 nodes and 30,544,475 edges as of July 1, 2022. PSKG is used for ad-hoc analyses and periodic reporting for several widely available COVID-19 vaccines. Analysis code using the knowledge graph is 80% shorter than an equivalent implementation written entirely in Python, and runs over 200 times faster.

CONCLUSIONS

Organizing safety data into a concise model of nodes, properties, and edge relationships has greatly simplified analysis code by removing complex parsing and transformation algorithms from individual analyses and instead managing these centrally. The adoption of the knowledge graph transformed how the team answers key scientific and medical questions. Whereas previously an analysis would involve aggregating and transforming primary datasets from scratch to answer a specific question, the team can now iterate easily and respond as quickly as requests evolve (e.g., "Produce vaccine-X safety profile for adverse event-Y by country instead of age-range").

摘要

背景

知识图谱非常适合对复杂、非结构化和多源数据进行建模,并有助于对其进行分析。在 COVID-19 大流行期间,将不良事件数据整合到知识图谱中,以支持疫苗安全监测,并灵活应对紧急卫生当局的问题。在这里,我们提供使用公共数据源的这个上市后安全系统的详细信息。除了数据表示形式多样化的挑战外,COVID-19 疫苗的不良事件报告产生了前所未有的大量数据;比以往所有疫苗的不良事件数量多一个数量级。患者安全知识图谱(PSKG)是一个强大的数据存储库,可容纳不良事件数据的数量,并协调主要监测数据源。

方法

我们设计了一个语义模型来表示关键安全概念。我们构建了一个提取-转换-加载(ETL)数据管道来解析和导入主要公共数据源;对齐疫苗名称等关键要素;整合监管活动医学词典(MedDRA);并应用质量指标。PSKG 部署在 Neo4J 图形数据库中,并通过 Web 界面和应用程序编程接口(API)提供。

结果

截至 2022 年 7 月 1 日,我们每周从 250 个国家/地区导入和对齐不良事件数据和疫苗暴露数据,生成一个具有 4,340,980 个节点和 30,544,475 条边的图。PSKG 用于几种广泛可用的 COVID-19 疫苗的临时分析和定期报告。使用知识图谱的分析代码比完全用 Python 编写的等效实现短 80%,并且运行速度快 200 多倍。

结论

将安全数据组织成节点、属性和边关系的简洁模型,通过从各个分析中删除复杂的解析和转换算法,并集中管理这些算法,极大地简化了分析代码。知识图谱的采用改变了团队回答关键科学和医学问题的方式。以前,分析需要从头开始汇总和转换主要数据集来回答特定问题,而现在团队可以轻松迭代,并根据请求的变化快速响应(例如,“按国家而不是年龄范围生成不良事件-Y 的疫苗-X 安全性概况”)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/89ce1d7ac981/12911_2023_2409_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/a5f3a3cb16d8/12911_2023_2409_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/4f243ae8ded8/12911_2023_2409_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/0246d0f5d922/12911_2023_2409_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/f72d1a2d78c3/12911_2023_2409_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/f4fd72a8bdf0/12911_2023_2409_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/93b17446ee52/12911_2023_2409_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/f64e15fcbc1c/12911_2023_2409_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/42e6913b4000/12911_2023_2409_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/acd4f49d8898/12911_2023_2409_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/16f18a7c48ff/12911_2023_2409_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/c528f20e50eb/12911_2023_2409_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/4d164699d51f/12911_2023_2409_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/40d0cee5418b/12911_2023_2409_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/89ce1d7ac981/12911_2023_2409_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/a5f3a3cb16d8/12911_2023_2409_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/4f243ae8ded8/12911_2023_2409_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/0246d0f5d922/12911_2023_2409_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/f72d1a2d78c3/12911_2023_2409_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/f4fd72a8bdf0/12911_2023_2409_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/93b17446ee52/12911_2023_2409_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/f64e15fcbc1c/12911_2023_2409_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/42e6913b4000/12911_2023_2409_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/acd4f49d8898/12911_2023_2409_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/16f18a7c48ff/12911_2023_2409_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/c528f20e50eb/12911_2023_2409_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/4d164699d51f/12911_2023_2409_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/40d0cee5418b/12911_2023_2409_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6b8/10768450/89ce1d7ac981/12911_2023_2409_Fig14_HTML.jpg

相似文献

1
A patient safety knowledge graph supporting vaccine product development.支持疫苗产品开发的患者安全知识图谱。
BMC Med Inform Decis Mak. 2024 Jan 4;24(1):10. doi: 10.1186/s12911-023-02409-8.
2
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.免疫接种后安全性监测:疫苗不良事件报告系统(VAERS)——美国,1991 - 2001年
MMWR Surveill Summ. 2003 Jan 24;52(1):1-24.
3
Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.利用数据挖掘技术对疫苗不良事件报告系统(VAERS)中的安全信号进行前瞻性早期检测:2010-2011 年季节性流感病毒疫苗接种后发热性惊厥的病例研究。
Drug Saf. 2013 Jul;36(7):547-56. doi: 10.1007/s40264-013-0051-9.
4
A signal detection method for temporal variation of adverse effect with vaccine adverse event reporting system data.一种基于疫苗不良事件报告系统数据的不良效应时间变化的信号检测方法。
BMC Med Inform Decis Mak. 2017 Jul 5;17(Suppl 2):76. doi: 10.1186/s12911-017-0472-y.
5
Assessing the Safety of COVID-19 Vaccines: A Primer.评估 COVID-19 疫苗的安全性:入门介绍。
Drug Saf. 2020 Dec;43(12):1205-1210. doi: 10.1007/s40264-020-01002-6. Epub 2020 Sep 30.
6
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).疫苗不良事件报告系统(VAERS)中的安全性监测。
Vaccine. 2015 Aug 26;33(36):4398-405. doi: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.mRNA 疫苗预防 COVID-19 的真实世界安全性概况:VAERS 数据库分析。
Vaccine. 2023 May 2;41(18):2879-2886. doi: 10.1016/j.vaccine.2023.03.054. Epub 2023 Mar 28.
9
Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing.优化疫苗不良事件报告系统中的信号管理:使用体征、症状和自然语言处理对 COVID-19 疫苗进行概念验证
Drug Saf. 2024 Feb;47(2):173-182. doi: 10.1007/s40264-023-01381-6. Epub 2023 Dec 7.
10
Safety profile of - 17 years of GSK's passive post-marketing surveillance.葛兰素史克17年被动上市后监测的安全性概况。
Expert Rev Vaccines. 2020 Aug;19(8):771-779. doi: 10.1080/14760584.2020.1800458. Epub 2020 Aug 10.

引用本文的文献

1
Pharmacovigilance - Technological Advancements, Recent Developments and Innovations.药物警戒——技术进步、最新进展与创新
Curr Drug Saf. 2025;20(4):423-449. doi: 10.2174/0115748863356840250112181406.
2
The WHO Algorithm for Causality Assessment of Adverse Effects Following Immunization with Genetic-Based Anti-COVID-19 Vaccines: Pitfalls and Suggestions for Improvement.世界卫生组织基于基因的抗COVID-19疫苗接种后不良反应因果关系评估算法:陷阱与改进建议
J Clin Med. 2024 Nov 30;13(23):7291. doi: 10.3390/jcm13237291.

本文引用的文献

1
BioBERT: a pre-trained biomedical language representation model for biomedical text mining.BioBERT:一种用于生物医学文本挖掘的预训练生物医学语言表示模型。
Bioinformatics. 2020 Feb 15;36(4):1234-1240. doi: 10.1093/bioinformatics/btz682.
2
Knowledge graph prediction of unknown adverse drug reactions and validation in electronic health records.知识图谱预测未知药物不良反应并在电子健康记录中验证。
Sci Rep. 2017 Nov 27;7(1):16416. doi: 10.1038/s41598-017-16674-x.
3
MIMIC-III, a freely accessible critical care database.MIMIC-III,一个免费获取的重症监护数据库。
Sci Data. 2016 May 24;3:160035. doi: 10.1038/sdata.2016.35.
4
Data-driven Approach to Detect and Predict Adverse Drug Reactions.检测和预测药物不良反应的数据驱动方法。
Curr Pharm Des. 2016;22(23):3498-526. doi: 10.2174/1381612822666160509125047.
5
Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms.用于识别药物不良反应并阐明其潜在生物学机制的系统生物学方法。
Wiley Interdiscip Rev Syst Biol Med. 2016 Mar-Apr;8(2):104-22. doi: 10.1002/wsbm.1323. Epub 2015 Nov 12.
6
Normalized names for clinical drugs: RxNorm at 6 years.临床药物的规范化名称:RxNorm 六年发展
J Am Med Inform Assoc. 2011 Jul-Aug;18(4):441-8. doi: 10.1136/amiajnl-2011-000116. Epub 2011 Apr 21.
7
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.使用比例报告比(PRR)从自发药物不良反应报告中生成信号。
Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):483-6. doi: 10.1002/pds.677.
8
The medical dictionary for regulatory activities (MedDRA).监管活动医学词典(MedDRA)。
Drug Saf. 1999 Feb;20(2):109-17. doi: 10.2165/00002018-199920020-00002.